Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy
© 2023. Korea Nanotechnology Research Society (KoNTRS)..
Cancer immunotherapy, which harnesses the power of the immune system, has shown immense promise in the fight against malignancies. Messenger RNA (mRNA) stands as a versatile instrument in this context, with its capacity to encode tumor-associated antigens (TAAs), immune cell receptors, cytokines, and antibodies. Nevertheless, the inherent structural instability of mRNA requires the development of effective delivery systems. Lipid nanoparticles (LNPs) have emerged as significant candidates for mRNA delivery in cancer immunotherapy, providing both protection to the mRNA and enhanced intracellular delivery efficiency. In this review, we offer a comprehensive summary of the recent advancements in LNP-based mRNA delivery systems, with a focus on strategies for optimizing the design and delivery of mRNA-encoded therapeutics in cancer treatment. Furthermore, we delve into the challenges encountered in this field and contemplate future perspectives, aiming to improve the safety and efficacy of LNP-based mRNA cancer immunotherapies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Nano convergence - 10(2023), 1 vom: 07. Aug., Seite 36 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Han, Jieun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer immunotherapy |
|---|
| Anmerkungen: |
Date Revised 21.11.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1186/s40580-023-00385-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360502229 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360502229 | ||
| 003 | DE-627 | ||
| 005 | 20231226083141.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40580-023-00385-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360502229 | ||
| 035 | |a (NLM)37550567 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Han, Jieun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lipid nanoparticle-based mRNA delivery systems for cancer immunotherapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023. Korea Nanotechnology Research Society (KoNTRS). | ||
| 520 | |a Cancer immunotherapy, which harnesses the power of the immune system, has shown immense promise in the fight against malignancies. Messenger RNA (mRNA) stands as a versatile instrument in this context, with its capacity to encode tumor-associated antigens (TAAs), immune cell receptors, cytokines, and antibodies. Nevertheless, the inherent structural instability of mRNA requires the development of effective delivery systems. Lipid nanoparticles (LNPs) have emerged as significant candidates for mRNA delivery in cancer immunotherapy, providing both protection to the mRNA and enhanced intracellular delivery efficiency. In this review, we offer a comprehensive summary of the recent advancements in LNP-based mRNA delivery systems, with a focus on strategies for optimizing the design and delivery of mRNA-encoded therapeutics in cancer treatment. Furthermore, we delve into the challenges encountered in this field and contemplate future perspectives, aiming to improve the safety and efficacy of LNP-based mRNA cancer immunotherapies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer immunotherapy | |
| 650 | 4 | |a Lipid nanoparticles (LNPs) | |
| 650 | 4 | |a Messenger RNA (mRNA) | |
| 650 | 4 | |a Tumor-associated antigens (TAAs) | |
| 700 | 1 | |a Lim, Jaesung |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chi-Pin James |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Jun-Hyeok |e verfasserin |4 aut | |
| 700 | 1 | |a Shin, Ha Eun |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Se-Na |e verfasserin |4 aut | |
| 700 | 1 | |a Jeong, Dooyong |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Sang Hwi |e verfasserin |4 aut | |
| 700 | 1 | |a Chun, Bok-Hwan |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Chun Gwon |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Wooram |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nano convergence |d 2014 |g 10(2023), 1 vom: 07. Aug., Seite 36 |w (DE-627)NLM268899150 |x 2196-5404 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:1 |g day:07 |g month:08 |g pages:36 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s40580-023-00385-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 1 |b 07 |c 08 |h 36 | ||